MYOVIEW 30ML
Peaktetrofosmin
NDAINJECTIONINJECTABLE
Approved
Feb 1996
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
MYOVIEW 30ML (tetrofosmin) is (99mtc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. First approved in 1996.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYOVIEW (tetrofosmin) is a radionuclide imaging agent approved in 1996 for diagnostic assessment of coronary artery disease. It is a lipophilic, cationic technetium-99m complex that passively diffuses into myocardial cells and is actively retained by intact mitochondria, reflecting myocardial perfusion and viability. The drug is administered by intravenous injection for single-photon emission computed tomography (SPECT) imaging.
Peak3.8 years to LOE
Product is in peak lifecycle stage with 3.9 years of patent protection remaining; commercial teams will focus on maximizing market share before generic and biosimilar competition intensifies.
Mechanism of Action
(99mTc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. After intravenous injection, it is distributed within the myocardium…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.